GlassScriptPhysician profile
Scott Condie
NPI 1891749560
$4,681.89
in general payments reported to CMS, 2019-2025
26 companies · $858 in 2025
The $858 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $940 · 2022: $1,054 · 2023: $808 · 2024: $1,021 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,587.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,911.58 | 2021-2025 | |
| Ucb, INC. | $510.60 | 2021-2025 | Bimzelx |
| Pfizer INC. | $280.80 | 2021-2025 | |
| Janssen Biotech, INC. | $265.76 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $258.44 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $210.57 | 2021-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $177.27 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $169.20 | 2021-2024 | |
| Journey Medical Corporation | $162.73 | 2021-2022 | |
| Dermavant Sciences, INC. | $142.37 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $94.03 | 2021-2024 | |
| Almirall LLC | $79.05 | 2022-2025 | Seysara |
| Genzyme Corporation | $52.66 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $49.25 | 2023-2025 | Zoryve |
| Biofrontera INC. | $49.23 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.76 | 2021 | |
| Organon LLC | $37.11 | 2025 | Vtama |
| Dermira, INC. | $34.07 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.74 | 2021 | |
| Krystal Biotech INC | $24.09 | 2024 | Vyjuvek |
| Sun Pharmaceutical Industries INC. | $19.63 | 2022 | |
| Verrica Pharmaceuticals INC. | $19.52 | 2025 | Ycanth |
| Strata Skin Sciences, INC. | $18.10 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $15.16 | 2023 | Valchlor |
| Amgen INC. | $15.13 | 2025 | Otezla |
| Merz North America, INC. | $15.04 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Condie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.